Study Confirms That Dietary Flavonoids Reduce Risk of Ovarian Cancer(9/2/2008) Researchers from Italy have reported that high consumption of plant-based foods that contain flavonoids may reduce the risk of ovarian cancer by nearly half. These results were recently published in the August 15, 2008 issue of the International Journal of Cancer.
Fluctuation in Weight May Influence Risk Certain Cancers(4/10/2008) Researchers in Austria have reported that large weight gains or losses may influence an individual’s risk for developing certain types of cancer. Complete details of the study were published in the April 2008 issue of the Annals of Oncology.
Test Evaluating Combination of Biomarkers Highly Accurate in Detecting Ovarian Cancer(2/21/2008) Researchers from several US medical centers have reported that a test evaluating a combination of six biomarker appears to be highly accurate in detecting ovarian cancer. These results were recently published in the February 15, 2008 issue of Clinical Cancer Research.
Experience of Technician Affects Accuracy of Gynecologic Ultrasound in Ovarian Cancer Screening(2/15/2008) Researchers from the UK have reported that the expertise of the technician performing gynecologic ultrasound not only affects the accuracy of the test results but also initial management of patients with suspected ovarian cancer. These results were published in the February 2008 issue of The Lancet Oncology.
Oral Contraceptives Reduce Risk of Ovarian Cancer(2/7/2008) Researchers from the UK affiliated with the Collaborative Group on Epidemiology Studies of Ovarian Cancer have reported that oral contraceptives reduce the long-term risk of ovarian cancer and have prevented approximately 100,000 deaths from ovarian cancer. The details of this report appeared in the January 26, 2008 issue of the Lancet.
Further Evidence in Favor of Care for Ovarian Cancer Patients by Gynecologic Oncologists(2/5/2008) Researchers from several California academic medical centers have reported that patients under 55 years of age with Stages IC–II ovarian cancer were more likely to receive chemotherapy if they received treatment from a gynecologic oncologist. The details of this report appeared in the January, 2008 issue of Gynecologic Oncology.
Partial Hold on Telcyta® Development Removed(10/26/2007) The United States Food and Drug Administration (FDA) has removed the partial hold it had placed on the clinical development of Telik, Inc’s investigative small molecule Telcyta (canfosfamide HCL, TLK286).
Avastin® Can be Added Safely to First Line Chemotherapy for Ovarian Cancer(9/5/2007) Researchers from the Hoag Cancer Center and the Desert Regional Cancer Center in California have reported that an outpatient regimen of Taxol® (paclitaxel), Platinol® (carboplatin) and Avastin (bevacizumab) can safely be administered to patients with newly diagnosed ovarian cancer. The details of this study appeared in the July-August, 2007 issue of the International Journal of Gynecological Oncology.
Aranesp® and Epoetin Alfa Do Not Increase Blood Clots in Ovarian Cancer(5/2/2007) Researchers from the University of North Carolina have reported that use of Aranesp® (darbepoetin alfa) or epoetin alfa (Procrit® or Epogen®) does not appear to increase the risk of developing medical complications due to blood clots in patients with ovarian cancer who have chemotherapy-induced anemia. The details of this study appeared in the May 2007 issue of Gynecologic Oncology.
Surgery for Isolated Nodal Metastasis of Ovarian Cancer Provides Favorable Survival(4/10/2007) Researchers from John Hopkins and the Cedar-Sinai Medical Center have reported that patients with ovarian cancer who have a recurrence in a lymph node have favorable survival when the involved lymph node is entirely or almost entirely removed. The details of this study appeared in the March 2007, issue of Gynecologic Oncology.
Results from ChemoFX® Associated with Survival in Ovarian Cancer Patients(6/4/2008) Researchers affiliated with Precision Therapeutics and Columbia University have reported that a test of chemoresponsiveness (ChemoFX®) can predict survival of patients with advanced ovarian cancer. The details of this study were presented at the 2008 meeting of the American Society of Clinical Oncology (ASCO) in Chicago May 30-June 3. ASCO has approved the advanced publication of these data.
Specialty Hospitals Associated with Improved Survival in Early Ovarian Cancer(3/19/2008) Researchers from the Netherlands have reported that hospitals specializing in care for ovarian cancer are associated with significantly improved survival for women with early ovarian cancer. These results were recently reported on March 11, 2008 in an early online publication in the Journal of the National Cancer Institute.
Statins at Time of Surgery May Improve Survival in Ovarian Cancer(3/17/2008) Researchers from the Cedars-Sinai Medical Center in Los Angeles have reported that the use of statins at the time of surgery among women with ovarian cancer improved progression-free and overall survival. These results were presented at the 2008 annual Society of Gynecologic Oncology (SGO) on March 13.
Further Evidence in Favor of Care for Ovarian Cancer Patients by Gynecologic Oncologists(2/5/2008) Researchers from several California academic medical centers have reported that patients under 55 years of age with Stages IC–II ovarian cancer were more likely to receive chemotherapy if they received treatment from a gynecologic oncologist. The details of this report appeared in the January, 2008 issue of Gynecologic Oncology.
Residual Tumor Predictive of Survival of Patients with Stage IV Ovarian Cancer(12/11/2007) Researchers affiliated with Gynecologic Oncology Group (GOG) have reported that patients with more than 5 cm residual disease after surgery have the shortest progression-free (PFS) and overall survivals (OS). The details of this study appeared in an early on-line publication in the Journal of Clinical Oncology on November 19, 2007.
Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers(3/18/2008) Researchers from the University of Alabama have reported that the administration of Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day administration. These results were recently reported at the 2008 annual Society of Gynecologic Oncologists meeting.
Thalomid® Improves Response to Hycamtin® for Recurrent Ovarian Cancer(3/4/2008) Researchers from the University of Minnesota have reported that the addition of Thalomid® (thalidomide) to Hycamtin® (topotecan) improves response rate in women with recurrent ovarian cancer. The details of this study were published in the January 15, 2008 issue of Cancer.
Further Evidence in Favor of Care for Ovarian Cancer Patients by Gynecologic Oncologists(2/5/2008) Researchers from several California academic medical centers have reported that patients under 55 years of age with Stages IC–II ovarian cancer were more likely to receive chemotherapy if they received treatment from a gynecologic oncologist. The details of this report appeared in the January, 2008 issue of Gynecologic Oncology.
Residual Tumor Predictive of Survival of Patients with Stage IV Ovarian Cancer(12/11/2007) Researchers affiliated with Gynecologic Oncology Group (GOG) have reported that patients with more than 5 cm residual disease after surgery have the shortest progression-free (PFS) and overall survivals (OS). The details of this study appeared in an early on-line publication in the Journal of Clinical Oncology on November 19, 2007.
Avastin® Associated Bowel Perforation Defined(12/4/2007) Researchers from the MD Anderson Cancer Center have reported that the incidence of bowel perforation among patients receiving Avastin (bevacizumab) for a variety of malignancies was 1.7%. The details of this study appeared in an early on-line publication in the Annals of Oncology on November 16, 2007.
Patient Home
